Combat Medical (Combat), a medical device company optimizing the delivery and efficacy of cancer drugs, today announced that it has raised £2.6 million in the first round of Series A funding to advance HIVEC®, a hyperthermic intravesical chemotherapy treatment, through Phase 3 clinical trials and towards FDA registration. The round was led by T&J Meyer Family Foundation and included investments from Varia Ventures, NW Angel Fund, and non-institutional investors family offices and individuals.
The funds will be used to further fund HIVEC HEAT, a pivotal FDA-registered trial currently underway to investigate the efficacy of the company’s HIVEC treatment for BCG-nonresponsive non-muscle invasive bladder cancer (NMIBC). The primary objective is to generate Phase 3 clinical data demonstrating that Combat’s patented HIVEC therapy is an effective, safe and tolerable alternative to the current standard of care, radical cystectomy.
Combat will use future funding to complete FDA registration, scale its business, expand existing clinical programs in advanced bladder cancer (HIVEC) and peritoneal cancer (HIPEC), and focus on entering the U.S. market.
Our installed base of over 350 systems and over 100,000 completed HIVEC treatments to date demonstrate efficacy and use as a safe and well-tolerated bladder-sparing alternative to radical cystectomy in BCG-unresponsive high-risk NMIBC. It sets a new standard for patient care and provides clinicians and payers with advanced and affordable options that can be easily incorporated into current treatment pathways. We are proud to have our investors on board as we move toward FDA approval. ”
Edward Bruce-White, Chief Executive Officer, Combat Medical
Balint Nemeth of the T&J Meyer Family Foundation added: “Combat Medical is leading the development and clinical use of device-assisted therapies that have the potential to disrupt current standards of care. The system is widely used in the clinic and is already impacting patient outcomes, so we are excited to support the company as it advances HIVEC through clinical trials.”
